AGT and heart failure: Novel agents like ARNIs (angiotensin receptor–neprilysin inhibitors) might confer dual benefits on the heart and kidney by reducing angiotensin II while enhancing beneficial natriuretic peptides; ongoing trials are examining their impact on renal outcomes in heart failure patients.